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Background/Aim: S-1 plus cisplatin is the standard first-line chemotherapy for metastatic 
gastric cancer (MGC) in Japan, but the relationship between dose intensity and antitumor 
effects remains unclear. Patients and Methods: We retrospectively studied 64 patients who 
received S-1 plus cisplatin for MGC from January 2006 to December 2010 in two Japanese 
hospitals. Results: The median relative dose intensity (RDI) of S-1 plus cisplatin was 87% 
(range, 59.5%-100%). The cut-off value of RDI of S-1 plus cisplatin was identified to be 80% 
by a receiver operating characteristic analysis of the tumor response. In the RDI<80% (n=19) 
and the RDI≥80% (n=45) groups, the response rates were 20.0% and 37.5% (p=0.182), the 
median survival times were 394 and 376 days (p=0.915), and the median progression-free 
survival (PFS) was 188 and 170 days (p=0.851), respectively. Conclusion: An appropriate RDI 
reduction may be permitted for patients with MGC in palliative settings.  
 
